Clinical Trial Update: Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the efficacy, tolerability, and safety of Azilect (rasagiline) in progressive supranuclear palsy has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Supranuclear Palsy

Drugs mentioned

• Azilect (rasagiline)

Snippet

Sponsor: Prof. Dr. Stefan Lorenzl | Conditions: Progressive Supranuclear Palsy | Phase 3 | Status: TERMINATED